The "Liberation" Of Science Yields A New Class Of Biopharma Leadership

By Matthew Pillar, Editor, Bioprocess Online

Current bear market in emerging biotech notwithstanding, there’s a longer-term trend in the biopharma space that’s inciting a bit of a talent exodus from Big Pharma to emerging bio. On episode 95 of the Business of Biotech podcast, Purespring Therapeutics CEO Richard Francis called that trend the “liberation” of science as he shared his motivation for leaving a C-suite career among the likes of Biogen, Sandoz, and Novartis for the challenge of leading a brand-new biopharma startup.